Literature DB >> 1306124

A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio.

G Tybring1, L Bertilsson.   

Abstract

After a single oral dose of racemic mephenytoin the S/R ratio in urine can be used to phenotype extensive (EM) and poor metabolizers (PM) of S-mephenytoin. We confirmed the increased S/R ratio by storage time in EM because of the hydrolysis of a conjugate of S-mephenytoin excreted in EM, but not in PM. The S/R ratio in the 0-8 h urine increased 8- to 127-fold (from 0.22 +/- 0.16 to 9.9 +/- 11.3) after acid treatment of urine from 30 EM, but there was no effect of acid in that of 12 PM. We suggest that the phenotype of mephenytoin in combination with debrisoquine can be determined in the 0-8 h urine by estimating the mephenytoin S/R ratio before and after acid treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1306124     DOI: 10.1097/00008571-199210000-00007

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  7 in total

1.  Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.

Authors:  S Hägg; O Spigset; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

2.  Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19.

Authors:  M Chang; G Tybring; M L Dahl; E Götharson; M Sagar; R Seensalu; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

3.  The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles.

Authors:  Amarjit S Chaudhry; Bhagwat Prasad; Yoshiyuki Shirasaka; Alison Fohner; David Finkelstein; Yiping Fan; Shuoguo Wang; Gang Wu; Eleni Aklillu; Sarah C Sim; Kenneth E Thummel; Erin G Schuetz
Journal:  Drug Metab Dispos       Date:  2015-05-28       Impact factor: 3.922

4.  Mephenytoin as a probe for CYP2C19 phenotyping:effect of sample storage, intra-individual reproducibility and occurrence of adverse events.

Authors:  W J Tamminga; J Wemer; B Oosterhuis; J Wieling; D J Touw; R A de Zeeuw; L F de Leij; J H Jonkman
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

5.  Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.

Authors:  Jónrit Halling; Maria S Petersen; Per Damkier; Flemming Nielsen; Philippe Grandjean; Pál Weihe; Stefan Lundgren; Mia Sandberg Lundblad; Kim Brøsen
Journal:  Eur J Clin Pharmacol       Date:  2005-07-16       Impact factor: 2.953

Review 6.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.

Authors:  D A Flockhart
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

Review 7.  Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.